|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|5.||Nephrotic Syndrome (Syndrome, Nephrotic)
|1.||Engert, Andreas: 83 articles (08/2015 - 01/2002)|
|2.||Younes, Anas: 70 articles (01/2016 - 01/2002)|
|3.||Diehl, Volker: 55 articles (08/2015 - 01/2002)|
|4.||Diehl, V: 40 articles (12/2013 - 01/2000)|
|5.||Borchmann, Peter: 37 articles (08/2015 - 11/2002)|
|6.||Engert, A: 32 articles (11/2015 - 01/2000)|
|7.||Bartlett, Nancy L: 31 articles (06/2015 - 02/2002)|
|8.||Brice, Pauline: 26 articles (12/2015 - 01/2002)|
|9.||Moskowitz, Craig H: 24 articles (08/2015 - 03/2004)|
|10.||Medeiros, L Jeffrey: 24 articles (03/2014 - 02/2002)|
|1.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/01/1988 - "Patients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and nitrosourea-containing regimens than patients with relapsing disease following a complete remission with MOPP. "
02/15/2002 - "Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen."
02/01/2010 - "If corroborated by further studies, therapeutic drug monitoring of doxorubicin may be warranted in patients with Hodgkin lymphoma."
02/01/2010 - "Despite many years of clinical use in Hodgkin lymphoma, no previous studies have evaluated the relationship between doxorubicin pharmacokinetics and clinical response. "
04/01/2007 - "A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)."
|2.||Bleomycin (Blenoxane)FDA LinkGeneric
07/01/1997 - "This study summarized results of treatment of the extraperitoneal lymphatic nodes in patients with Hodgkin's disease with infusion of oily form of bleomycin into the lymphatic vessels. "
07/01/1997 - "[A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes]."
04/11/2015 - "With respect to our predefined non-inferiority margin, bleomycin cannot be safely omitted either, and the standard of care for patients with early-stage favourable Hodgkin's lymphoma should remain ABVD followed by IFRT. "
01/01/2015 - "Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma."
10/01/2014 - "Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity."
|3.||Vinblastine (Vinblastine Sulfate)FDA Link
06/01/2011 - "Here he carried out his best known clinical study-the use of vinblastine sulphate in patients with Hodgkin lymphoma. "
05/01/1979 - "randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease."
06/01/1972 - "A randomized study of irradiation and vinblastine in stages I and II of Hodgkin's disease. "
04/01/2014 - "Severe neurotoxicity due to Vinblastine in Hodgkin lymphoma."
09/24/2010 - "In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. "
|4.||Procarbazine (Matulane)FDA Link
01/01/1996 - "Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine."
04/01/1991 - "In the other, the RRM attacks may have been associated with procarbazine therapy applied for Hodgkin's disease. "
09/01/1979 - "Procarbazine [N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride] is used to treat Hodgkin's disease. "
02/01/1979 - "From the incidence of patients with Hodgkin's disease (1 : 42 000) the calculated population dose of procarbazine is 5.12 micrograms/kg. Assuming equal sensitivity between the sexes we can calculate, for an estimated number of 30 000 genes, the induction of about 22 mutations per million children due to procarbazine treatment. "
02/01/1979 - "Procarbazine is used in drug-combination treatment of Hodgkin's disease. "
|5.||Vincristine (Oncovin)FDA LinkGeneric
09/05/2014 - "Unusual manifestations of vincristine neuropathy: report of two cases of hodgkin lymphoma."
11/01/2001 - "We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine. "
11/01/1982 - "The case history of a 24-year-old male with the nodular sclerosing form of Hodgkin's disease (stage IIE) who accidentally received an overdose of vincristine (25 mg, 0.39 mg/kg) is reported. "
04/08/1982 - "Fifteen patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface, during the first week of each month for 3 months). "
03/01/1980 - "Ten patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface during the first week of each month for 3 months). "
|6.||Prednisone (Sone)FDA LinkGeneric
10/31/1962 - "[Effect of large doses of prednisone on the clinical course of advanced forms of Hodgkin's disease]."
12/01/1957 - "[Acute malignant lymphogranuloma and its treatment with prednisone]."
01/01/1975 - "[Polychemotherapy without prednisone in Hodgkin's disease]."
05/01/1992 - "Of the 21 adolescent patients with acute lymphoblastic leukemia or Hodgkin disease who were to take prednisone as outpatients, 11 patients were found to be nonadherent to treatment (52%). "
07/01/1981 - "Four patients with diffuse histiocytic lymphoma (group 1) received prednisone for 5 days every 3 weeks for five courses, and five patients with Hodgkin's disease (group 2) received prednisone for 14 days every 4 weeks for six courses. "
|7.||Dacarbazine (DIC)FDA LinkGeneric
06/01/1990 - "DIC after bone marrow harvesting in a patient with Hodgkin's disease in remission."
01/01/2014 - "Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells."
12/01/2003 - "A psu dic(17;2)(p11.2;p21), leading to p53 deletion, was observed in a patient who developed a mixed cellularity Hodgkin's disease coexisting with the CLL/SLL in the same lymph node. "
12/22/1978 - "[DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)]."
07/01/2012 - "The cause of death was identified as intracerebral haemorrhage following DIC, Hodgkin's disease and recent delivery by caesarean section. "
|8.||Etoposide (VP 16)FDA LinkGeneric
04/01/1999 - "ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients."
11/15/1998 - "The effects of etoposide on testicular function in boys treated for Hodgkin's disease."
03/01/1993 - "This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease."
01/01/1990 - "The case of Vepesid overdosage in a patient with Hodgkin's disease."
01/01/1982 - "It is concluded that etoposide has significant activity particularly in Hodgkin's disease. "
|9.||Mechlorethamine (Nitrogen Mustard)FDA Link
10/01/1970 - "Long-term remission in Hodgkin's disease after nitrogen mustard therapy."
11/01/1959 - "[Clinical studies on nitrogen mustard and roentgen therapy of Hodgkin's disease]."
05/01/1998 - "[Hodgkin's disease in two children of mother treated with nitrogranulogen]."
12/01/1992 - "Four patients with fresh Hodgkin's disease were treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride (NH2-O). "
12/01/1992 - "[Four cases of Hodgkin's disease treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride]."
09/01/2012 - "A phase II study of brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma (cHL) showed an impressive overall response rate of 75 % with 34 % complete responses, and median remission duration of 20 months in complete responders. "
01/01/2013 - "Although durability of the remission needs further observation, this case illustrates the excellent efficacy of brentuximab vedotin in primary refractory Hodgkin lymphoma. "
11/01/2015 - "In chemosensitive relapsed Hodgkin lymphoma, addition of brentuximab vedotin after auto-HCT improved 2-year PFS (65 vs 45%) and can be considered as an option for maintenance therapy post auto-HCT, in select higher risk patients. "
08/01/2013 - "Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. "
10/15/2011 - "Second, the efficacy of SGN-35, particularly in Hodgkin lymphoma, might be attributed to its effect on the tumor microenvironment. "
|1.||Drug Therapy (Chemotherapy)
08/15/2012 - "Although most of the patients with Hodgkin's lymphoma (HL) can be cured by the current regimen of high-dose multiagent chemotherapy, the treatment causes high risks of later toxicities including secondary malignancies. "
04/01/2012 - "Most children and adolescents with newly diagnosed high-risk Hodgkin lymphoma (HL) will achieve remission and cure with conventional chemotherapy with or without radiation therapy. "
01/01/2011 - "Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. "
05/01/2008 - "Most patients with Hodgkin lymphoma (HL) can be cured with initial multiagent chemotherapy. "
01/01/2008 - "With the application of modern chemotherapy and radiation techniques, most patients with Hodgkin lymphoma can be cured, regardless of initial extent of disease. "
07/01/2010 - "Hodgkin's disease can be cured in most cases by radiotherapy. "
05/01/2010 - "The advent of effective chemo-radiotherapy has made Hodgkin Disease (HD) a highly curable malignancy, but the great improvement in survival rates allowed the observation in long-term survivors of several treatment complications. "
01/01/2008 - "Until very recently mantle field radiotherapy remained the gold standard for the treatment of favorable early-stage Hodgkin's lymphoma. "
11/01/2006 - "Radiotherapy is very effective in local control of Hodgkin's lymphoma. "
01/01/2004 - "Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. "
|3.||Combination Drug Therapy (Combination Chemotherapy)
07/15/1995 - "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy. "
02/01/1992 - "Study population comprised 107 patients with Hodgkin's disease treated with combination chemotherapy at the National Cancer Institute who relapsed after achieving a complete remission. "
01/01/1999 - "Complete remission rates of 70-90% can be achieved following combination chemotherapy for patients with advanced-stage Hodgkin's disease (HD). "
12/01/1998 - "The patients with advanced-stage Hodgkin's disease who did not achieve a complete remission from their initial treatment with combination chemotherapy have a dismal prognosis. "
01/01/1998 - "Although 90% of adults with advanced Hodgkin's disease (HD) achieve a complete remission with new polychemotherapy regimens such as BEACOPP, it is too early to assess how many patients ultimately can be cured. "
|4.||Stem Cell Transplantation
02/01/2011 - "Hodgkin's lymphoma (HL) can be cured in most of the patients, but in case of refractory disease or relapse after autologous stem cell transplantation (SCT) the prognosis becomes very poor. "
01/01/1995 - "Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD."
01/01/2012 - "Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's lymphoma (HL). "
05/01/2006 - "We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n = 9; MSD, n = 12). "
02/01/2003 - "Clinical and translational research initiatives that hold promise for children with Hodgkin disease in the future include: use of the WHO Classification System combining morphologic and biologic criteria; noninvasive staging procedures with increased sensitivity and specificity; development of a useful prognostic index to define groups for risk-adapted therapy; high-dose therapy with stem cell transplantation; and novel therapies."
01/01/2011 - "Radiation-induced thyroid disorders may develop in pediatric Hodgkin's lymphoma patients in complete remission starting as early as the first year after treatment and are dose-dependent. "
08/01/1989 - "The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432 patients achieving complete remission after treatment for stage I and II Hodgkin's disease at the Royal Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. "
01/01/1983 - "Peripheral lymphocyte chromosomes were analyzed in 55 consecutive patients with complete remission after treatment for Hodgkin's disease. "
07/24/2012 - "Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts."
01/01/1993 - "Eleven months after treatment, both Wegener's disease and Hodgkin's lymphoma remained in remission."